{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:24:09Z","timestamp":1791321849180,"version":"4.3.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,4,10]],"date-time":"2007-04-10T00:00:00Z","timestamp":1176163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1038\/sj.ijo.0803631","type":"journal-article","created":{"date-parts":[[2007,4,10]],"date-time":"2007-04-10T11:15:40Z","timestamp":1176203740000},"page":"1567-1570","source":"Crossref","is-referenced-by-count":84,"title":["Long-term persistence with orlistat and sibutramine in a population-based cohort"],"prefix":"10.1038","volume":"31","author":[{"given":"R","family":"Padwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kezouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Etminan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,4,10]]},"reference":[{"key":"BF0803631_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/nrd781","volume":"1","author":"C Farrigan","year":"2002","unstructured":"Farrigan C, Pang K . From the analysts's couch. Obesity market overview. Nat Rev Drug Discov 2002; 1: 257\u2013258.","journal-title":"Nat Rev Drug Discov"},{"key":"BF0803631_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/35007544","volume":"404","author":"GA Bray","year":"2000","unstructured":"Bray GA, Tartaglia LA . Medicinal strategies in the treatment of obesity. Nature 2000; 404: 672\u2013677.","journal-title":"Nature"},{"key":"BF0803631_CR3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"R Padwal","year":"2003","unstructured":"Padwal R, Li SK, Lau DCW . Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003; 27: 1437\u20131446.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF0803631_CR4","unstructured":"Medical News Today. Data Demonstrate Impact of Weight Loss with Sibutramine on Cardiovascular Risk Factors for Obese Patients, 2004 (Accessed April 6, 2006 at \n                    http:\/\/www.medicalnewstoday.com\/index.php?newsid=885\n                    \n                   )."},{"key":"BF0803631_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L . Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155\u2013161.","journal-title":"Diabetes Care"},{"key":"BF0803631_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jama.288.4.462","volume":"288","author":"CA Jackevicius","year":"2002","unstructured":"Jackevicius CA, Mamdani M, Tu JV . Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462\u2013467.","journal-title":"JAMA"},{"key":"BF0803631_CR7","first-page":"41","volume":"160","author":"JJ Caro","year":"1999","unstructured":"Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD . Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160: 41\u201346.","journal-title":"CMAJ"},{"key":"BF0803631_CR8","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMsa003087","volume":"346","author":"S Schneeweiss","year":"2002","unstructured":"Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB . Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002; 346: 822\u2013829.","journal-title":"N Engl J Med"},{"key":"BF0803631_CR9","first-page":"67","volume":"10","author":"AR Levy","year":"2003","unstructured":"Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D . Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol 2003; 10: 67\u201371.","journal-title":"Can J Clin Pharmacol"},{"key":"BF0803631_CR10","volume-title":"PCCF+ Version 3G User's Guide: Automated Geographic Coding Based on the Statistics Canada Postal Code Conversion Files","author":"R Wilkins","year":"2001","unstructured":"Wilkins R . PCCF+ Version 3G User's Guide: Automated Geographic Coding Based on the Statistics Canada Postal Code Conversion Files. Ottawa: Statistics Canada, 2001."},{"key":"BF0803631_CR11","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0149-2918(01)80110-7","volume":"23","author":"G Dailey","year":"2001","unstructured":"Dailey G, Kim MS, Lian JF . Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001; 23: 1311\u20131320.","journal-title":"Clin Ther"},{"key":"BF0803631_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ypmed.2004.04.040","volume":"39","author":"HM Blanck","year":"2004","unstructured":"Blanck HM, Khan LK, Serdula MK . Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. Prev Med 2004; 39: 1243\u20131248.","journal-title":"Prev Med"},{"key":"BF0803631_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T . Adherence to Medication. N Engl J Med 2005; 353: 487\u2013497.","journal-title":"N Engl J Med"},{"key":"BF0803631_CR14","unstructured":"National Heart, Lung, and Blood Institute Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1998; 1\u2013262."},{"key":"BF0803631_CR15","unstructured":"Obesity: the prevention identification, assessment and management of overweight and obesity in adults and children (draft). London, England: National Institute for Health and Clinical Excellence, 2006 (Accessed April 6, 2006 at \n                    www.nice.org.uk\/page.aspx?o=96572\n                    \n                  )."},{"key":"BF0803631_CR16","unstructured":"Orlistat: summary of product characteristics. London England: European Agency for the Evaluation of Medicinal Products, 2005 (Accessed April 6, 2006 at \n                    www.emea.eu.int\/humandocs\/PDFs\/EPAR\/Xenical\/H-154-PI-en.pdf\n                    \n                  )."},{"key":"BF0803631_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s002280100316","volume":"57","author":"B Beermann","year":"2001","unstructured":"Beermann B, Melander H, Sawe J, Ulleryd C, Dahlqvist R . Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. Eur J Clin Pharmacol 2001; 57: 309\u2013311.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF0803631_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1520-037X.2003.02633.x","volume":"6","author":"T Pearson","year":"2003","unstructured":"Pearson T, Kopin L . Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. Prev Cardiol 2003; 6: 204\u2013211.","journal-title":"Prev Cardiol"},{"key":"BF0803631_CR19","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"Blood Pressure Lowering Treatment Trialists' Collaboration","year":"2003","unstructured":"Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527\u20131535.","journal-title":"Lancet"},{"key":"BF0803631_CR20","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"Cholesterol Treatment Trialists' Collaborators","year":"2005","unstructured":"Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90\u2009056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267\u20131278.","journal-title":"Lancet"},{"key":"BF0803631_CR21","first-page":"1307","volume":"166","author":"E Wooltorton","year":"2002","unstructured":"Wooltorton E . Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002; 166: 1307\u20131308.","journal-title":"CMAJ"},{"key":"BF0803631_CR22","unstructured":"Health Canada reports back to public on safety profile of MERIDIA (sibutramine). Ottawa Ontario: Health Canada, 2003 (Accessed April 6, 2006 at \n                    www.hc-sc.gc.ca\/ahc-asc\/media\/advisories-avis\/2003\/2003_07_e.html\n                    \n                   )."},{"key":"BF0803631_CR23","unstructured":"Committee for Proprietary Medicinal Products opinion following an article 31 referral: Sibutramine. London, England: European Agency for the Evaluation of Medicinal Products, 2002 (Accessed April 6, 2006 at \n                    www.emea.eu.int\/pdfs\/human\/referral\/451401en.pdf\n                    \n                  )."},{"key":"BF0803631_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1463-1326.2004.00467.x","volume":"7","author":"BA Swinburn","year":"2005","unstructured":"Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab 2005; 7: 254\u2013262.","journal-title":"Diabetes Obes Metab"},{"key":"BF0803631_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1467-789X.2005.00211.x","volume":"6","author":"DR Foxcroft","year":"2005","unstructured":"Foxcroft DR . Orlistat for the treatment of obesity: cost utility model. Obes Rev 2005; 6: 323\u2013328.","journal-title":"Obes Rev"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/0803631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/0803631","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/0803631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T07:41:15Z","timestamp":1684222875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/0803631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["BF0803631"],"URL":"https:\/\/doi.org\/10.1038\/sj.ijo.0803631","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,10]]}}}